Hope on the Horizon: Psychedelics Offer Potential for Transforming Mental Health Treatments
), which this week acquired Adelia Therapeutics, a transformational move that broadened addressable indications in its pipeline and strengthened its scientific team. Cybin has a three-pillar approach, its initial sights set on treating major depression disorder (MDD) now expanded to address additional indication as well through innovative psychedelic therapeutics development and unique delivery technologies. Cybin stands shoulder-to-shoulder with peers striving for a world of better mental well-being such as COMPASS Pathways Plc (NASDAQ:CMPS), Mind Medicine Inc (OTC:MMEDF) (NEO: MMED), N...
Source: benzinga.com